132 related articles for article (PubMed ID: 17554019)
21. Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation.
Fuentes-Pananá EM; Ling PD
J Virol; 1998 Jan; 72(1):693-700. PubMed ID: 9420275
[TBL] [Abstract][Full Text] [Related]
22. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.
Ling PD; Hsieh JJ; Ruf IK; Rawlins DR; Hayward SD
J Virol; 1994 Sep; 68(9):5375-83. PubMed ID: 8057421
[TBL] [Abstract][Full Text] [Related]
23. Molecular analysis of latent membrane protein 1 in patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan.
Tabata YHibi S; Teramura T; Kuriyama K; Yagi T; Todo S; Sawada T; Imashuku S
Leuk Lymphoma; 2000 Jul; 38(3-4):373-80. PubMed ID: 10830744
[TBL] [Abstract][Full Text] [Related]
24. Identification of functional differences between prototype Epstein-Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells.
Dawson CW; Eliopoulos AG; Blake SM; Barker R; Young LS
Virology; 2000 Jun; 272(1):204-17. PubMed ID: 10873763
[TBL] [Abstract][Full Text] [Related]
25. Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor.
Murata T; Noda C; Narita Y; Watanabe T; Yoshida M; Ashio K; Sato Y; Goshima F; Kanda T; Yoshiyama H; Tsurumi T; Kimura H
J Virol; 2016 Apr; 90(8):3873-3889. PubMed ID: 26819314
[TBL] [Abstract][Full Text] [Related]
26. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.
Larcher C; Bernhard D; Schaadt E; Adler B; Ausserlechner MJ; Mitterer M; Huemer HP
Haematologica; 2003 Dec; 88(12):1324-35. PubMed ID: 14687985
[TBL] [Abstract][Full Text] [Related]
27. A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus.
Chen H; Hutt-Fletcher L; Cao L; Hayward SD
J Virol; 2003 Apr; 77(7):4139-48. PubMed ID: 12634372
[TBL] [Abstract][Full Text] [Related]
28. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
Nilsson T; Sjöblom A; Masucci MG; Rymo L
Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
[TBL] [Abstract][Full Text] [Related]
29. Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway.
Fuentes-Pananá EM; Peng R; Brewer G; Tan J; Ling PD
J Virol; 2000 Sep; 74(17):8166-75. PubMed ID: 10933728
[TBL] [Abstract][Full Text] [Related]
30. Antisense to Epstein Barr Virus-encoded LMP1 does not affect the transcription of viral and cellular proliferation-related genes, but induces phenotypic effects on EBV-transformed B lymphocytes.
Masciarelli S; Mattioli B; Galletti R; Samoggia P; Chichiarelli S; Mearini G; Mattia E
Oncogene; 2002 Jun; 21(26):4166-70. PubMed ID: 12037673
[TBL] [Abstract][Full Text] [Related]
31. The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promoters.
Groves AK; Cotter MA; Subramanian C; Robertson ES
J Virol; 2001 Oct; 75(19):9446-57. PubMed ID: 11533207
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha.
Wakisaka N; Kondo S; Yoshizaki T; Murono S; Furukawa M; Pagano JS
Mol Cell Biol; 2004 Jun; 24(12):5223-34. PubMed ID: 15169887
[TBL] [Abstract][Full Text] [Related]
33. The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5.
Tierney R; Kirby H; Nagra J; Rickinson A; Bell A
J Virol; 2000 Nov; 74(22):10458-67. PubMed ID: 11044090
[TBL] [Abstract][Full Text] [Related]
34. Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.
Murray RJ; Young LS; Calender A; Gregory CD; Rowe M; Lenoir GM; Rickinson AB
J Virol; 1988 Mar; 62(3):894-901. PubMed ID: 2828684
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of Epstein-Barr virus with BamHI "f" variant and XhoI-loss of LMP1 gene in nasopharyngeal carcinoma].
Han AJ; Zong YS; Zhang M; Cao SM; Lin SX; Liang YJ
Zhonghua Bing Li Xue Za Zhi; 2003 Dec; 32(6):534-8. PubMed ID: 14761599
[TBL] [Abstract][Full Text] [Related]
36. The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes.
Johnson RJ; Stack M; Hazlewood SA; Jones M; Blackmore CG; Hu LF; Rowe M
J Virol; 1998 May; 72(5):4038-48. PubMed ID: 9557692
[TBL] [Abstract][Full Text] [Related]
37. Identification of a promoter for the latent membrane protein 1 gene of Epstein-Barr virus that is specifically activated in human epithelial cells.
Chang MH; Ng CK; Lin YJ; Liang CL; Chung PJ; ChenML ; Tyan YS; Hsu CY; Shu CH; Chang YS
DNA Cell Biol; 1997 Jul; 16(7):829-37. PubMed ID: 9260926
[TBL] [Abstract][Full Text] [Related]
38. Molecular and functional analysis of the Epstein-Barr virus LMP1 oncogene promoter in lymphoproliferative diseases.
Rothenberger S; Bachmann E; Knecht H
Exp Hematol; 1997 Dec; 25(13):1326-32. PubMed ID: 9406991
[TBL] [Abstract][Full Text] [Related]
39. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors.
Chen H; Lee JM; Zong Y; Borowitz M; Ng MH; Ambinder RF; Hayward SD
J Virol; 2001 Mar; 75(6):2929-37. PubMed ID: 11222718
[TBL] [Abstract][Full Text] [Related]
40. [Study of sequence variations of Epstein-Barr virus LMP1 gene in nasopharyngeal carcinoma].
Lin SX; Zong YS; Zhang M; Han AJ; Zhong BL; Liang YJ
Zhonghua Bing Li Xue Za Zhi; 2005 Dec; 34(12):791-5. PubMed ID: 16545188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
